

Formulary Actions Effective: 07/01/2025											Rationale of Changes			
Drug Attributes							Formulary Status		Utilization Management					
							Medicaid		Medicaid					
Category	Brand Name	Generic Name	Strength	Dosage Form	Route	Brand Status	Current Status	Action	Current Status	Action	MEDICAID	Committee Actions	Optional Benefit Exclusion	Client Communication - Standard Medicaid
ANTIMIGRAINE PREPARATIONS	IMITREX	SUMATRIPTAN	20 MG	SPRAY	NASAL	GENERIC	F	S=F	QL	C=QL	Clinical/Safety Strategy	P&T 4Q24		QL: LIMITED TO 18 SPRAYERS PER 30 DAYS
AUTONOMIC NERVOUS SYSTEM DISORDERS	RYSTIGGO	ROZANOLIXIZUMAB-NOLI	280 MG/2ML	VIAL	SUBCUTANE.	SSB	NC	S=NC	PA	C=PA	Clinical/Safety Strategy	P&T 2Q25	Non-Self Administered Drug (NSA)	
AUTONOMIC NERVOUS SYSTEM DISORDERS	RYSTIGGO	ROZANOLIXIZUMAB-NOLI	420 MG/3ML	VIAL	SUBCUTANE.	SSB	NC	S=NC	PA	C=PA	Clinical/Safety Strategy	P&T 2Q25	Non-Self Administered Drug (NSA)	
AUTONOMIC NERVOUS SYSTEM DISORDERS	RYSTIGGO	ROZANOLIXIZUMAB-NOLI	560 MG/4ML	VIAL	SUBCUTANE.	SSB	NC	S=NC	PA	C=PA	Clinical/Safety Strategy	P&T 2Q25	Non-Self Administered Drug (NSA)	
AUTONOMIC NERVOUS SYSTEM DISORDERS	RYSTIGGO	ROZANOLIXIZUMAB-NOLI	840 MG/6ML	VIAL	SUBCUTANE.	SSB	NC	S=NC	PA	C=PA	Clinical/Safety Strategy	P&T 2Q25	Non-Self Administered Drug (NSA)	
AUTONOMIC NERVOUS SYSTEM DISORDERS	VYVGART	EFGARTIGIMOD ALFA-FCAB	400MG/20ML	VIAL	INTRAVEN.	SSB	NC	S=NC	PA	C=PA	Clinical/Safety Strategy	P&T 2Q25	Non-Self Administered Drug (NSA)	
AUTONOMIC NERVOUS SYSTEM DISORDERS	VYVGART HYTRULO	EFGARTIGIMOD-HYALURONIDAS-QVFC	1008MG/5.6	VIAL	SUBCUTANE.	SSB	NC	S=NC	PA	C=PA	Clinical/Safety Strategy	P&T 2Q25	Non-Self Administered Drug (NSA)	
AUTONOMIC NERVOUS SYSTEM DISORDERS	VYVGART HYTRULO	EFGARTIGIMOD-HYALURONIDAS-QVFC	1000MG/5ML	SYRINGE	SUBCUTANE.	SSB	NC	S=NC	PA	C=PA	Clinical/Safety Strategy	P&T 2Q25		
CARDIOVASCULAR DISEASE - HYPERTENSION	PHENOXYBENZAMINE HCL	PHENOXYBENZAMINE HCL	10 MG	CAPSULE	ORAL	GENERIC	F	S=F	PA	C=PA	Clinical/Safety Strategy	P&T 2Q25		
CONTRACEPTION/OXYTOCICS	ANNOVERA	SEGESTERONE AC/ETHIN ESTRADIOL	.15-.013MG	VAG RING	VAGINAL	SSB	NC	S=NC	QL ST	S=QL D=ST	Miscellaneous	Ad-Hoc Formulary Maintenance		
CONTRACEPTION/OXYTOCICS	BALCOLTRA	LEVONORGEST/ETH.ESTRADIOL/IRON	0.1-0.02MG	TABLET	ORAL	MSB	F	S=F	QL ST	S=QL D=ST	Miscellaneous	Ad-Hoc Formulary Maintenance		
CONTRACEPTION/OXYTOCICS	DROSPIRENONE-ETH ESTRA-LEVOMEF	DROSPIR/ETH ESTRA/LEVOMEFOL CA	3-0.02(24)	TABLET	ORAL	GENERIC	NC	S=NC	ST	D=ST	Miscellaneous	Ad-Hoc Formulary Maintenance		
CONTRACEPTION/OXYTOCICS	DROSPIRENONE-ETH ESTRA-LEVOMEF	DROSPIR/ETH ESTRA/LEVOMEFOL CA	3-0.03(21)	TABLET	ORAL	GENERIC	NC	S=NC	ST	D=ST	Miscellaneous	Ad-Hoc Formulary Maintenance		
CONTRACEPTION/OXYTOCICS	ESTROSTEP FE	NORETHINDRONE-E.ESTRADIOL-IRON	5-7-9-7	TABLET	ORAL	MSB	NC	S=NC	ST	D=ST	Miscellaneous	Ad-Hoc Formulary Maintenance		
CONTRACEPTION/OXYTOCICS	LEVONORG-ETH ESTRAD ETH ESTRAD	L-NORGEST/E.ESTRADIOL-E.ESTRAD	0.15MG(84)	TBDSPK 3MO	ORAL	GENERIC	NC	S=NC	ST	D=ST	Miscellaneous	Ad-Hoc Formulary Maintenance		
CONTRACEPTION/OXYTOCICS	LO LOESTRIN FE	NORETHINDRONE-E.ESTRADIOL-IRON	1MG-10(24)	TABLET	ORAL	SSB	F	S=F	ST	D=ST	Miscellaneous	Ad-Hoc Formulary Maintenance		
CONTRACEPTION/OXYTOCICS	LOESTRIN	NORETHINDRONE AC/ETH ESTRADIOL	1.5-0.03MG	TABLET	ORAL	MSB	NC	S=NC	ST	D=ST	Miscellaneous	Ad-Hoc Formulary Maintenance		
CONTRACEPTION/OXYTOCICS	LOESTRIN	NORETHINDRONE AC/ETH ESTRADIOL	1MG-20MCG	TABLET	ORAL	MSB	NC	S=NC	ST	D=ST	Miscellaneous	Ad-Hoc Formulary Maintenance		
CONTRACEPTION/OXYTOCICS	LOESTRIN FE	NORETHINDRONE-E.ESTRADIOL-IRON	1.5-30(21)	TABLET	ORAL	MSB	NC	S=NC	ST	D=ST	Miscellaneous	Ad-Hoc Formulary Maintenance		
CONTRACEPTION/OXYTOCICS	LOESTRIN FE	NORETHINDRONE-E.ESTRADIOL-IRON	1MG-20(21)	TABLET	ORAL	MSB	NC	S=NC	ST	D=ST	Miscellaneous	Ad-Hoc Formulary Maintenance		
CONTRACEPTION/OXYTOCICS	LOSEASONIQUE	L-NORGEST/E.ESTRADIOL-E.ESTRAD	100-20(84)	TBDSPK 3MO	ORAL	MSB	NC	S=NC	QL ST	S=QL D=ST	Miscellaneous	Ad-Hoc Formulary Maintenance		

CONTRACEPTION/OXYTOCICS	MIRCETTE	DESOG-E. ESTRADIOL/E. ESTRADIOL	21-5 (28)	TABLET	ORAL	MSB	NC	S=NC	ST	D=ST	Miscellaneous	Ad-Hoc Formulary Maintenance		
CONTRACEPTION/OXYTOCICS	NATAZIA	ESTRADIOL VALERATE/DIENOGEST	3-2-1(28)	TABLET	ORAL	SSB	NC	S=NC	ST	D=ST	Miscellaneous	Ad-Hoc Formulary Maintenance		
CONTRACEPTION/OXYTOCICS	NEXTSTELLIS	DROSPIRENONE/ESTETROL	3-14.2(28)	TABLET	ORAL	SSB	NC	S=NC	QL ST	S=QL D=ST	Miscellaneous	Ad-Hoc Formulary Maintenance		
CONTRACEPTION/OXYTOCICS	NORETHINDRONE-E. ESTRADIOL-IRON	NORETHINDRONE-E. ESTRADIOL-IRON	1MG-20(24)	TAB CHEW	ORAL	GENERIC	NC	S=NC	ST	D=ST	Miscellaneous	Ad-Hoc Formulary Maintenance		
CONTRACEPTION/OXYTOCICS	NORETHIN-ETH. ESTRA-FERROUS FUM	NORETH-ETHINYL ESTRADIOL/IRON	0.8-25(24)	TAB CHEW	ORAL	GENERIC	F	S=F	ST	D=ST	Miscellaneous	Ad-Hoc Formulary Maintenance		
CONTRACEPTION/OXYTOCICS	ORTHO TRI-CYCLEN	NORGESTIMATE-ETHINYL ESTRADIOL	7DAYSX3 28	TABLET	ORAL	MSB	NC	S=NC	ST	D=ST	Miscellaneous	Ad-Hoc Formulary Maintenance		
CONTRACEPTION/OXYTOCICS	ORTHO-NOVUM	NORETHINDRONE-ETHIN. ESTRADIOL	7 DAYS X 3	TABLET	ORAL	MSB	NC	S=NC	ST	D=ST	Miscellaneous	Ad-Hoc Formulary Maintenance		
CONTRACEPTION/OXYTOCICS	SEASONIQUE	L-NORGEST/E. ESTRADIOL-E. ESTRAD	150-30(84)	TBDSPK 3MO	ORAL	MSB	NC	S=NC	QL ST	S=QL D=ST	Miscellaneous	Ad-Hoc Formulary Maintenance		
CONTRACEPTION/OXYTOCICS	SLYND	DROSPIRENONE	4 MG (28)	TABLET	ORAL	SSB	NC	S=NC	QL ST	S=QL D=ST	Miscellaneous	Ad-Hoc Formulary Maintenance		
CONTRACEPTION/OXYTOCICS	TAYTULLA	NORETHINDRONE-E. ESTRADIOL-IRON	1MG-20(24)	CAPSULE	ORAL	MSB	NC	S=NC	ST	D=ST	Miscellaneous	Ad-Hoc Formulary Maintenance		
DERMATOLOGY - ANTIINFLAMMATORY	ZORYVE	ROFLUMILAST	0.15 %	CREAM (G)	TOPICAL	SSB	NC	S=NC	PA	C=PA	Trade Relations Strategy	P&T 2Q25		
DERMATOLOGY - PSORIASIS/ECZEMA	VTAMA	TAPINAROF	1 %	CREAM (G)	TOPICAL	SSB	NC	S=NC	PA	C=PA	Trade Relations Strategy	P&T 2Q25		
DIABETES	BAQSIMI	GLUCAGON	3 MG	SPRAY	NASAL	SSB	NC	C=F	QL	S=QL	Trade Relations Strategy	FBRC FEB 2025		
DIABETES	EVERSENSE E3 SENSOR-HLDR	GLUCOSE SENSOR,IMPLANT/DEXAMET		EACH	SUBCUTANE.	NON DRUG	NC	S=NC	NONE	A=PA	Trade Relations Strategy	FBRC JAN 2025		
DIABETES	EVERSENSE SENSOR-HOLDER	GLUCOSE SENSOR,IMPLANT/DEXAMET		EACH	SUBCUTANE.	NON DRUG	NC	S=NC	NONE	A=PA	Trade Relations Strategy	FBRC JAN 2025		
ENDOCRINE DISORDER - OTHER	GENOTROPIN	SOMATROPIN	12 MG/ML	CARTRIDGE	SUBCUTANE.	SSB	NC	S=NC	PA	C=PA	Trade Relations Strategy	P&T 2Q25		
ENDOCRINE DISORDER - OTHER	GENOTROPIN	SOMATROPIN	1.2MG/0.25	SYRINGE	SUBCUTANE.	SSB	NC	S=NC	PA	C=PA	Trade Relations Strategy	P&T 2Q25		
ENDOCRINE DISORDER - OTHER	GENOTROPIN	SOMATROPIN	1.4MG/0.25	SYRINGE	SUBCUTANE.	SSB	NC	S=NC	PA	C=PA	Trade Relations Strategy	P&T 2Q25		
ENDOCRINE DISORDER - OTHER	GENOTROPIN	SOMATROPIN	1.6MG/0.25	SYRINGE	SUBCUTANE.	SSB	NC	S=NC	PA	C=PA	Trade Relations Strategy	P&T 2Q25		
ENDOCRINE DISORDER - OTHER	GENOTROPIN	SOMATROPIN	1.8MG/0.25	SYRINGE	SUBCUTANE.	SSB	NC	S=NC	PA	C=PA	Trade Relations Strategy	P&T 2Q25		
ENDOCRINE DISORDER - OTHER	GENOTROPIN	SOMATROPIN	2MG/0.25ML	SYRINGE	SUBCUTANE.	SSB	NC	S=NC	PA	C=PA	Trade Relations Strategy	P&T 2Q25		
ENDOCRINE DISORDER - OTHER	GENOTROPIN	SOMATROPIN	0.2MG/0.25	SYRINGE	SUBCUTANE.	SSB	NC	S=NC	PA	C=PA	Trade Relations Strategy	P&T 2Q25		
ENDOCRINE DISORDER - OTHER	GENOTROPIN	SOMATROPIN	0.4MG/0.25	SYRINGE	SUBCUTANE.	SSB	NC	S=NC	PA	C=PA	Trade Relations Strategy	P&T 2Q25		

ENDOCRINE DISORDER - OTHER	GENOTROPIN	SOMATROPIN	0.6MG/0.25	SYRINGE	SUBCUTANE.	SSB	NC	S=NC	PA	C=PA	Trade Relations Strategy	P&T 2Q25		
ENDOCRINE DISORDER - OTHER	GENOTROPIN	SOMATROPIN	0.8MG/0.25	SYRINGE	SUBCUTANE.	SSB	NC	S=NC	PA	C=PA	Trade Relations Strategy	P&T 2Q25		
ENDOCRINE DISORDER - OTHER	GENOTROPIN	SOMATROPIN	1MG/0.25ML	SYRINGE	SUBCUTANE.	SSB	NC	S=NC	PA	C=PA	Trade Relations Strategy	P&T 2Q25		
ENDOCRINE DISORDER - OTHER	GENOTROPIN	SOMATROPIN	5 MG/ML	CARTRIDGE	SUBCUTANE.	SSB	NC	S=NC	PA	C=PA	Trade Relations Strategy	P&T 2Q25		
ENDOCRINE DISORDER - OTHER	HUMATROPE	SOMATROPIN	12 MG	CARTRIDGE	INJECTION	SSB	NC	S=NC	PA	C=PA	Trade Relations Strategy	P&T 2Q25		
ENDOCRINE DISORDER - OTHER	HUMATROPE	SOMATROPIN	24 MG	CARTRIDGE	INJECTION	SSB	NC	S=NC	PA	C=PA	Trade Relations Strategy	P&T 2Q25		
ENDOCRINE DISORDER - OTHER	HUMATROPE	SOMATROPIN	5 MG	VIAL	INJECTION	SSB	NC	S=NC	PA	C=PA	Trade Relations Strategy	P&T 2Q25		
ENDOCRINE DISORDER - OTHER	HUMATROPE	SOMATROPIN	6 MG	CARTRIDGE	INJECTION	SSB	NC	S=NC	PA	C=PA	Trade Relations Strategy	P&T 2Q25		
ENDOCRINE DISORDER - OTHER	INCRELEX	MECASERMIN	10 MG/ML	VIAL	SUBCUTANE.	SSB	F	S=F	PA	C=PA	Trade Relations Strategy	P&T 2Q25		
ENDOCRINE DISORDER - OTHER	NGENLA	SOMATROGON-GHLA	24MG/1.2ML	PEN INJCTR	SUBCUTANE.	SSB	NC	S=NC	PA	C=PA	Trade Relations Strategy	P&T 2Q25		
ENDOCRINE DISORDER - OTHER	NGENLA	SOMATROGON-GHLA	60MG/1.2ML	PEN INJCTR	SUBCUTANE.	SSB	NC	S=NC	PA	C=PA	Trade Relations Strategy	P&T 2Q25		
ENDOCRINE DISORDER - OTHER	NORDITROPIN FLEXPPO	SOMATROPIN	5 MG/1.5ML	PEN INJCTR	SUBCUTANE.	SSB	F	S=F	PA	C=PA	Trade Relations Strategy	P&T 2Q25		
ENDOCRINE DISORDER - OTHER	NORDITROPIN FLEXPPO	SOMATROPIN	10MG/1.5ML	PEN INJCTR	SUBCUTANE.	SSB	F	S=F	PA	C=PA	Trade Relations Strategy	P&T 2Q25		
ENDOCRINE DISORDER - OTHER	NORDITROPIN FLEXPPO	SOMATROPIN	15MG/1.5ML	PEN INJCTR	SUBCUTANE.	SSB	F	S=F	PA	C=PA	Trade Relations Strategy	P&T 2Q25		
ENDOCRINE DISORDER - OTHER	NORDITROPIN FLEXPPO	SOMATROPIN	30 MG/3 ML	PEN INJCTR	SUBCUTANE.	SSB	F	S=F	PA	C=PA	Trade Relations Strategy	P&T 2Q25		
ENDOCRINE DISORDER - OTHER	NUTROPIN AQ NUSPIN	SOMATROPIN	10 MG/2 ML	PEN INJCTR	SUBCUTANE.	SSB	NC	S=NC	PA	C=PA	Trade Relations Strategy	P&T 2Q25		
ENDOCRINE DISORDER - OTHER	NUTROPIN AQ NUSPIN	SOMATROPIN	5 MG/2 ML	PEN INJCTR	SUBCUTANE.	SSB	NC	S=NC	PA	C=PA	Trade Relations Strategy	P&T 2Q25		
ENDOCRINE DISORDER - OTHER	NUTROPIN AQ NUSPIN	SOMATROPIN	20 MG/2 ML	PEN INJCTR	SUBCUTANE.	SSB	NC	S=NC	PA	C=PA	Trade Relations Strategy	P&T 2Q25		
ENDOCRINE DISORDER - OTHER	OMNITROPE	SOMATROPIN	10MG/1.5ML	CARTRIDGE	SUBCUTANE.	SSB	NC	S=NC	PA	C=PA	Trade Relations Strategy	P&T 2Q25		
ENDOCRINE DISORDER - OTHER	OMNITROPE	SOMATROPIN	5 MG/1.5ML	CARTRIDGE	SUBCUTANE.	SSB	NC	S=NC	PA	C=PA	Trade Relations Strategy	P&T 2Q25		
ENDOCRINE DISORDER - OTHER	OMNITROPE	SOMATROPIN	5.8 MG	VIAL	SUBCUTANE.	SSB	NC	S=NC	PA	C=PA	Trade Relations Strategy	P&T 2Q25		
ENDOCRINE DISORDER - OTHER	SAIZEN	SOMATROPIN	5 MG	VIAL	SUBCUTANE.	SSB	NC	S=NC	PA	C=PA	Trade Relations Strategy	P&T 2Q25		
ENDOCRINE DISORDER - OTHER	SAIZEN	SOMATROPIN	8.8 MG	VIAL	SUBCUTANE.	SSB	NC	S=NC	PA	C=PA	Trade Relations Strategy	P&T 2Q25		

ENDOCRINE DISORDER - OTHER	SAIZEN-SAIZENPREP	SOMATROPIN	8.8MG/1.51	CARTRIDGE	SUBCUTANE.	SSB	NC	S=NC	PA	C=PA	Trade Relations Strategy	P&T 2Q25		
ENDOCRINE DISORDER - OTHER	SEROSTIM	SOMATROPIN	5 MG	VIAL	SUBCUTANE.	SSB	F	S=F	PA	C=PA	Trade Relations Strategy	P&T 2Q25		
ENDOCRINE DISORDER - OTHER	SEROSTIM	SOMATROPIN	6 MG	VIAL	SUBCUTANE.	SSB	F	S=F	PA	C=PA	Trade Relations Strategy	P&T 2Q25		
ENDOCRINE DISORDER - OTHER	SEROSTIM	SOMATROPIN	4 MG	VIAL	SUBCUTANE.	SSB	F	S=F	PA	C=PA	Trade Relations Strategy	P&T 2Q25		
ENDOCRINE DISORDER - OTHER	SKYTROFA	LONAPEGSSOMATROPIN-TCGD	3 MG	CARTRIDGE	SUBCUTANE.	SSB	NC	S=NC	PA	C=PA	Trade Relations Strategy	P&T 2Q25		
ENDOCRINE DISORDER - OTHER	SKYTROFA	LONAPEGSSOMATROPIN-TCGD	3.6 MG	CARTRIDGE	SUBCUTANE.	SSB	NC	S=NC	PA	C=PA	Trade Relations Strategy	P&T 2Q25		
ENDOCRINE DISORDER - OTHER	SKYTROFA	LONAPEGSSOMATROPIN-TCGD	4.3 MG	CARTRIDGE	SUBCUTANE.	SSB	NC	S=NC	PA	C=PA	Trade Relations Strategy	P&T 2Q25		
ENDOCRINE DISORDER - OTHER	SKYTROFA	LONAPEGSSOMATROPIN-TCGD	5.2 MG	CARTRIDGE	SUBCUTANE.	SSB	NC	S=NC	PA	C=PA	Trade Relations Strategy	P&T 2Q25		
ENDOCRINE DISORDER - OTHER	SKYTROFA	LONAPEGSSOMATROPIN-TCGD	6.3 MG	CARTRIDGE	SUBCUTANE.	SSB	NC	S=NC	PA	C=PA	Trade Relations Strategy	P&T 2Q25		
ENDOCRINE DISORDER - OTHER	SKYTROFA	LONAPEGSSOMATROPIN-TCGD	7.6 MG	CARTRIDGE	SUBCUTANE.	SSB	NC	S=NC	PA	C=PA	Trade Relations Strategy	P&T 2Q25		
ENDOCRINE DISORDER - OTHER	SKYTROFA	LONAPEGSSOMATROPIN-TCGD	9.1 MG	CARTRIDGE	SUBCUTANE.	SSB	NC	S=NC	PA	C=PA	Trade Relations Strategy	P&T 2Q25		
ENDOCRINE DISORDER - OTHER	SKYTROFA	LONAPEGSSOMATROPIN-TCGD	11 MG	CARTRIDGE	SUBCUTANE.	SSB	NC	S=NC	PA	C=PA	Trade Relations Strategy	P&T 2Q25		
ENDOCRINE DISORDER - OTHER	SKYTROFA	LONAPEGSSOMATROPIN-TCGD	13.3 MG	CARTRIDGE	SUBCUTANE.	SSB	NC	S=NC	PA	C=PA	Trade Relations Strategy	P&T 2Q25		
ENDOCRINE DISORDER - OTHER	SOGROYA	SOMAPACITAN-BECO	10MG/1.5ML	PEN INJCTR	SUBCUTANE.	SSB	NC	S=NC	PA	C=PA	Trade Relations Strategy	P&T 2Q25		
ENDOCRINE DISORDER - OTHER	SOGROYA	SOMAPACITAN-BECO	5 MG/1.5ML	PEN INJCTR	SUBCUTANE.	SSB	NC	S=NC	PA	C=PA	Trade Relations Strategy	P&T 2Q25		
ENDOCRINE DISORDER - OTHER	SOGROYA	SOMAPACITAN-BECO	15MG/1.5ML	PEN INJCTR	SUBCUTANE.	SSB	NC	S=NC	PA	C=PA	Trade Relations Strategy	P&T 2Q25		
ENDOCRINE DISORDER - OTHER	ZOMACTON	SOMATROPIN	5 MG	VIAL	SUBCUTANE.	SSB	NC	S=NC	PA	C=PA	Trade Relations Strategy	P&T 2Q25		
ENDOCRINE DISORDER - OTHER	ZOMACTON	SOMATROPIN	10 MG	VIAL	SUBCUTANE.	SSB	NC	S=NC	PA	C=PA	Trade Relations Strategy	P&T 2Q25		
EYE - GENERAL DISORDERS	VEVVE	CYCLOSPORINE	0.1 %	DROPS	OPHTHALMIC	SSB	NC	S=NC	PA	C=PA	Trade Relations Strategy	P&T 2Q25		
EYE - GLAUCOMA	VYZULTA	LATANOPROSTENE BUNOD	0.024 %	DROPS	OPHTHALMIC	SSB	NC	S=NC	QL ST	S=ST C=QL	Clinical/Safety Strategy	P&T 1Q25		QL: LIMITED TO 2.5 ML PER 30 DAYS
HEMATOLOGICAL DISORDERS	EPYSQLI	ECULIZUMAB-AAGH	300MG/30ML	VIAL	INTRAVEN.	SSB	NC	S=NC	PA	C=PA	Trade Relations Strategy	P&T 2Q25	Non-Self Administered Drug (NSA)	
HEMATOLOGICAL DISORDERS	SOLIRIS	ECULIZUMAB	300MG/30ML	VIAL	INTRAVEN.	SSB	NC	S=NC	PA	C=PA	Clinical/Safety Strategy	P&T 2Q25	Non-Self Administered Drug (NSA)	
HEMATOLOGICAL DISORDERS	ULTOMIRIS	RAVULIZUMAB-CWVZ	300 MG/3ML	VIAL	INTRAVEN.	SSB	NC	S=NC	PA	C=PA	Clinical/Safety Strategy	P&T 2Q25	Non-Self Administered Drug (NSA)	

HEMATOLOGICAL DISORDERS	ULTOMIRIS	RAVULIZUMAB-CWVZ	1100 MG/11	VIAL	INTRAVEN.	SSB	NC	S=NC	PA	C=PA	Clinical/Safety Strategy	P&T 2Q25	Non-Self Administered Drug (NSA)	
HEMATOLOGICAL DISORDERS	ULTOMIRIS	RAVULIZUMAB-CWVZ	300MG/30ML	VIAL	INTRAVEN.	SSB	NC	S=NC	PA	C=PA	Clinical/Safety Strategy	P&T 2Q25	Non-Self Administered Drug (NSA)	
HEMATOLOGICAL DISORDERS	ZILBRYSQ	ZILUCOPLAN SODIUM	16.6/0.416	SYRINGE	SUBCUTANE.	SSB	NC	S=NC	PA	C=PA	Clinical/Safety Strategy	P&T 2Q25		
HEMATOLOGICAL DISORDERS	ZILBRYSQ	ZILUCOPLAN SODIUM	23/0.574ML	SYRINGE	SUBCUTANE.	SSB	NC	S=NC	PA	C=PA	Clinical/Safety Strategy	P&T 2Q25		
HEMATOLOGICAL DISORDERS	ZILBRYSQ	ZILUCOPLAN SODIUM	32.4/0.81	SYRINGE	SUBCUTANE.	SSB	NC	S=NC	PA	C=PA	Clinical/Safety Strategy	P&T 2Q25		
INFECTIOUS DISEASE - BACTERIAL	DOXYCYCLINE IR-DR	DOXYCYCLINE MONOHYDRATE	40 MG	CAP IR DR	ORAL	GENERIC	NC	S=NC	AGE QL ST	D=AGE D=QL D=ST A=PA	Clinical/Safety Strategy	P&T 1Q25		
INFLAMMATORY DISEASE	ACTEMRA	TOCILIZUMAB	80 MG/4 ML	VIAL	INTRAVEN.	SSB	NC	S=NC	PA	C=PA	Clinical/Safety Strategy	P&T 2Q25	Non-Self Administered Drug (NSA)	
INFLAMMATORY DISEASE	ACTEMRA	TOCILIZUMAB	200MG/10ML	VIAL	INTRAVEN.	SSB	NC	S=NC	PA	C=PA	Clinical/Safety Strategy	P&T 2Q25	Non-Self Administered Drug (NSA)	
INFLAMMATORY DISEASE	ACTEMRA	TOCILIZUMAB	400MG/20ML	VIAL	INTRAVEN.	SSB	NC	S=NC	PA	C=PA	Clinical/Safety Strategy	P&T 2Q25	Non-Self Administered Drug (NSA)	
INFLAMMATORY DISEASE	ACTEMRA	TOCILIZUMAB	162 MG/0.9	SYRINGE	SUBCUTANE.	SSB	F	S=F	PA	C=PA	Clinical/Safety Strategy	P&T 2Q25		
INFLAMMATORY DISEASE	ACTEMRA ACTPEN	TOCILIZUMAB	162 MG/0.9	PEN INJECTR	SUBCUTANE.	SSB	F	S=F	PA	C=PA	Clinical/Safety Strategy	P&T 2Q25		
INFLAMMATORY DISEASE	BERINERT	C1 ESTERASE INHIBITOR	500 (5 ML)	VIAL	INTRAVEN.	SSB	F	S=F	PA	C=PA	Trade Relations Strategy	P&T 2Q25		
INFLAMMATORY DISEASE	ICATIBANT	ICATIBANT ACETATE	30 MG/3 ML	SYRINGE	SUBCUTANE.	GENERIC	F	S=F	PA	C=PA	Trade Relations Strategy	P&T 2Q25		
INFLAMMATORY DISEASE	KALBITOR	ECALLANTIDE	10MG/ML(1)	VIAL	SUBCUTANE.	SSB	NC	S=NC	PA	C=PA	Trade Relations Strategy	P&T 2Q25	Non-Self Administered Drug (NSA)	
INFLAMMATORY DISEASE	RUCONEST	C1 ESTERASE INHIBITOR, RECOMB	2100 UNIT	VIAL	INTRAVEN.	SSB	F	S=F	PA	C=PA	Trade Relations Strategy	P&T 2Q25		
INFLAMMATORY DISEASE	TYENNE	TOCILIZUMAB-AAZG	80 MG/4 ML	VIAL	INTRAVEN.	SSB	NC	S=NC	PA	C=PA	Clinical/Safety Strategy	P&T 2Q25	Non-Self Administered Drug (NSA)	
INFLAMMATORY DISEASE	TYENNE	TOCILIZUMAB-AAZG	200MG/10ML	VIAL	INTRAVEN.	SSB	NC	S=NC	PA	C=PA	Clinical/Safety Strategy	P&T 2Q25	Non-Self Administered Drug (NSA)	
INFLAMMATORY DISEASE	TYENNE	TOCILIZUMAB-AAZG	400MG/20ML	VIAL	INTRAVEN.	SSB	NC	S=NC	PA	C=PA	Clinical/Safety Strategy	P&T 2Q25	Non-Self Administered Drug (NSA)	
INFLAMMATORY DISEASE	TYENNE	TOCILIZUMAB-AAZG	162 MG/0.9	SYRINGE	SUBCUTANE.	SSB	NC	S=NC	PA	C=PA	Clinical/Safety Strategy	P&T 2Q25		
INFLAMMATORY DISEASE	TYENNE AUTOINJECTOR	TOCILIZUMAB-AAZG	162 MG/0.9	PEN INJECTR	SUBCUTANE.	SSB	NC	S=NC	PA	C=PA	Clinical/Safety Strategy	P&T 2Q25		
MISCELLANEOUS AGENTS	REZDIFFRA	RESMETIROM	60 MG	TABLET	ORAL	SSB	NC	S=NC	PA	C=PA	Clinical/Safety Strategy	P&T 2Q25		
MISCELLANEOUS AGENTS	REZDIFFRA	RESMETIROM	80 MG	TABLET	ORAL	SSB	NC	S=NC	PA	C=PA	Clinical/Safety Strategy	P&T 2Q25		
MISCELLANEOUS AGENTS	REZDIFFRA	RESMETIROM	100 MG	TABLET	ORAL	SSB	NC	S=NC	PA	C=PA	Clinical/Safety Strategy	P&T 2Q25		

PAIN MANAGEMENT - ANALGESICS	JOURNAVX	SUZETRIGINE	50 MG	TABLET	ORAL	SSB	NC	S=NC	PA	C=PA	Clinical/Safety Strategy	P&T 2Q25		
UPPER GASTROINTESTINAL DISORDERS - ULCER DISEASE	ESOMEPRAZOLE MAGNESIUM	ESOMEPRAZOLE MAGNESIUM	2.5 MG	SUSPDR PKT	ORAL	GENERIC	F	S=F	QL ST	S=QL D=ST	Trade Relations Strategy	P&T 2Q25		
UPPER GASTROINTESTINAL DISORDERS - ULCER DISEASE	ESOMEPRAZOLE MAGNESIUM	ESOMEPRAZOLE MAGNESIUM	5 MG	SUSPDR PKT	ORAL	GENERIC	F	S=F	QL ST	S=QL D=ST	Trade Relations Strategy	P&T 2Q25		
UPPER GASTROINTESTINAL DISORDERS - ULCER DISEASE	ESOMEPRAZOLE MAGNESIUM	ESOMEPRAZOLE MAGNESIUM	20 MG	SUSPDR PKT	ORAL	GENERIC	F	S=F	QL ST	S=QL D=ST	Trade Relations Strategy	P&T 2Q25		
UPPER GASTROINTESTINAL DISORDERS - ULCER DISEASE	ESOMEPRAZOLE MAGNESIUM	ESOMEPRAZOLE MAGNESIUM	40 MG	SUSPDR PKT	ORAL	GENERIC	F	S=F	QL ST	S=QL D=ST	Trade Relations Strategy	P&T 2Q25		
UPPER GASTROINTESTINAL DISORDERS - ULCER DISEASE	ESOMEPRAZOLE MAGNESIUM	ESOMEPRAZOLE MAGNESIUM	10 MG	SUSPDR PKT	ORAL	GENERIC	F	S=F	QL ST	S=QL D=ST	Trade Relations Strategy	P&T 2Q25		
WEIGHT REDUCTION	WEGOVY	SEMAGLUTIDE	0.25MG/0.5	PEN INJCTR	SUBCUTANE.	SSB	NC	S=NC	PA	C=PA	Clinical/Safety Strategy	P&T 2Q25	Antiobesity	
WEIGHT REDUCTION	WEGOVY	SEMAGLUTIDE	0.5MG/.5ML	PEN INJCTR	SUBCUTANE.	SSB	NC	S=NC	PA	C=PA	Clinical/Safety Strategy	P&T 2Q25	Antiobesity	
WEIGHT REDUCTION	WEGOVY	SEMAGLUTIDE	1 MG/0.5ML	PEN INJCTR	SUBCUTANE.	SSB	NC	S=NC	PA	C=PA	Clinical/Safety Strategy	P&T 2Q25	Antiobesity	
WEIGHT REDUCTION	WEGOVY	SEMAGLUTIDE	1.7MG/0.75	PEN INJCTR	SUBCUTANE.	SSB	NC	S=NC	PA	C=PA	Clinical/Safety Strategy	P&T 2Q25	Antiobesity	
WEIGHT REDUCTION	WEGOVY	SEMAGLUTIDE	2.4MG/0.75	PEN INJCTR	SUBCUTANE.	SSB	NC	S=NC	PA	C=PA	Clinical/Safety Strategy	P&T 2Q25	Antiobesity	

Formulary Actions Effective: 07/01/2025													Rationale of Changes				
Drug Attributes								Formulary Status		Utilization Management							
								Marketplace (HIE)		HIE							
Category	Brand Name	Generic Name	Strength	Dosage Form	Route	Brand Status	NDC	Current Status	Action	Current Status	Action	COMMERCIAL	Committee Actions	Optional Benefit Exclusion	Optional Formulary Exclusion (HIE)	Client Communication - HIE	
AMPHINOMETICS	SYNALPIN 120	PRAMLINIDE ACETATE	2700/2.7ML	PEN/INJECT	SUBCUTANE	SSB	310662702	2	C=3	NONE	NONE	Trade Relations Strategy	FDR JAN 2025				
INCRETINOMETICS	BYDUREON BCSE	EXENATIDE MICROSPHERES	2MG/0.85ML	AUTO INJECT	SUBCUTANE	SSB	310654001	2	C=3	PA	S=PA	Trade Relations Strategy	FDR JAN 2025				
							310654004 310654085										
RAPID-ACTING INSULINE	NOVOLOG	INSULIN ASPART	100U/ML	VIAL	SUBCUTANE	MSB	160210011 160750111	3	C=NG	QL ST	S=QL S=ST	Low Net Cost Strategy	Miscellaneous			Multi-Source Brand Exclusion	
RAPID-ACTING INSULINE	NOVOLOG FLEXPEN	INSULIN ASPART	Strength	INSULIN PEN	SUBCUTANE	MSB	160210112 160210125 160633910	3	C=NG	QL ST	S=QL S=ST	Low Net Cost Strategy	Miscellaneous			Multi-Source Brand Exclusion	
RAPID-ACTING INSULINE	NOVOLOG MIX 70-30	INSULIN ASPART PROT/INSULIN ASP	70-30U/ML	VIAL	SUBCUTANE	MSB	160220011 160588512	3	C=NG	QL ST	S=QL S=ST	Low Net Cost Strategy	Miscellaneous			Multi-Source Brand Exclusion	
RAPID-ACTING INSULINE	NOVOLOG MIX 70-30 FLEXPEN	INSULIN ASPART PROT/INSULIN ASP	70-30U/ML	INSULIN PEN	SUBCUTANE	MSB	160220125 160606019	3	C=NG	QL ST	S=QL S=ST	Low Net Cost Strategy	Miscellaneous			Multi-Source Brand Exclusion	
RAPID-ACTING INSULINE	NOVOLOG PENFILL	INSULIN ASPART	100U/ML	CARTRIDGE	SUBCUTANE	MSB	160330312	3	C=NG	QL ST	S=QL S=ST	Low Net Cost Strategy	Miscellaneous			Multi-Source Brand Exclusion	
THYROID AGENTS	ADTHYZA	THYROID_PORK	120 MG	TABLET	ORAL	MSB	24338000990	3	C=NG	ST	S=ST	Low Net Cost Strategy	Miscellaneous			Multi-Source Brand Exclusion	
THYROID AGENTS	ADTHYZA	THYROID_PORK	60 MG	TABLET	ORAL	MSB	24338000790	3	C=NG	ST	S=ST	Low Net Cost Strategy	Miscellaneous			Multi-Source Brand Exclusion	
THYROID AGENTS	ADTHYZA	THYROID_PORK	15 MG	TABLET	ORAL	MSB	24338000590	3	C=NG	ST	S=ST	Low Net Cost Strategy	Miscellaneous			Multi-Source Brand Exclusion	
THYROID AGENTS	ADTHYZA	THYROID_PORK	30 MG	TABLET	ORAL	MSB	24338000890	3	C=NG	E	S=E	Low Net Cost Strategy	Miscellaneous			Multi-Source Brand Exclusion	
THYROID AGENTS	ADTHYZA	THYROID_PORK	90 MG	TABLET	ORAL	MSB	24338000690	3	C=NG	E	S=E	Low Net Cost Strategy	Miscellaneous			Multi-Source Brand Exclusion	

Note: The drug names listed are for reference purposes and denote action on the chemical entity unless otherwise specified. Where generic and brand products for a chemical entity co-exist, coverage and copayment for each will be a function of plan benefit design.

FORMULARY		UTILIZATION MANAGEMENT (UM)		OPTIONAL BENEFIT EXCLUSION
Formulary Status	Formulary Actions	UM Definition	UM Actions	Coverage for each category will be a function of plan benefit design. These products may be excluded on client benefits. Formulary and UM decisions only apply for clients who choose to provide coverage for these drug categories.
F = Formulary	C = Change	AGE = Age restriction	A = Add UM	Antiobesity
NF = Non-Formulary	E = Excluded drug from formulary	QL = Quantity Limit	D = Delete UM	Cosmetic Indications
E = Excluded	S = Sustain	ST = Step Therapy	C = Change UM	Dietary Supplements and Non-Drug Products
NC = Not covered		PA = Prior Authorization	E = Excluded drug from formulary	Drugs to Treat Impotency or Sexual Dysfunction
S = Specialty		HST= Hard Step (Step without grandfathering member must try preferred agents)	S = Sustain UM	Infertility
Non-S = Non-Specialty				Medical Foods: Dietary supplements, Enteral Feeding, Infant formula
				Non-Self Administered Drug (NSA)
				Ostomy Supplies
				Class O = Over the Counter Products
				Class Q = Products that are neither drugs nor devices, such as dietary supplements (including prenatal and other vitamins), medical foods, herbal preparations, and bulk flavorings or colorants
				Diagnostics